Insights - Bellus hosted their Chronic Cough KOL meeting this morning. It was paneled by: Jacky Smith: lead investigator of Bellus Phase 2 trials Denis Garceau: Bellus VP of … Continue Reading
Read NowInsights - Last week, Bellus (BLUSF) rallied from $1.50 range to over $2.00, touching a high of $2.31. This all happened on heavy volume. Remember, we first … Continue Reading
Read NowInsights - Adverum (ADVM) has rallied year to date from $3.50 to $10/share as the market is picking up on the gene therapy story. With data in … Continue Reading
Premium: Read NowInsights - Acer Therapeutics (ACER) has a PDUFA date on June 25, 2019 for the treatment of vascular Ehlers-Danlos syndrome (“vEDS”). vEDS is a serious rare disease … Continue Reading
Premium: Read NowInsights - Spring Bank (SBPH) presented data for their Phase 2 ACHIEVE trial at EASL conference today, including their 200mg cohort. Data was in line with expectations and confirms … Continue Reading
Read NowInsights - This morning Aldeyra released topline data for their Phase 3 candidate reproxalap in allergic conjunctivitis. The company showed statistical significance in both primary and secondary endpoints Primary … Continue Reading
Read NowInsights - Spring Bank provided a business update earlier this week to discuss 2019 development plant for their immune-modulator inarigivir in treating Hepatitis B. Although the company also discussed … Continue Reading
Premium: Read Now
